Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.
Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.
复制标题
乳腺癌 1 中扩增的下调有助于索拉非尼对人肝细胞癌的抗肿瘤作用。
DOI:
10.18632/oncotarget.8812
复制
发表时间:
2016-05-17
期刊:
影响因子:
--
通讯作者:
Yu C
中科院分区:
文献类型:
--
作者:
Li M;Wang W;Dan Y;Tong Z;Chen W;Qin L;Liu K;Li W;Mo P;Yu C
Multi-kinase inhibitor sorafenib represents a major breakthrough in the therapy of advanced hepatocellular carcinoma (HCC). Amplified in breast cancer 1 (AIB1) is frequently overexpressed in human HCC tissues and promotes HCC progression. In this study, we investigated the effects of sorafenib on AIB1 expression and the role of AIB1 in anti-tumor effects of sorafenib. We found that sorafenib downregulated AIB1 protein expression by inhibiting AIB1 mRNA translation through simultaneously blocking eIF4E and mTOR/p70S6K/RP-S6 signaling. Knockdown of AIB1 significantly promoted sorafenib-induced cell death, whereas overexpression of AIB1 substantially diminished sorafenib-induced cell death. Downregulation of AIB1 contributed to sorafenib-induced cell death at least in part through upregulating the levels of reactive oxygen species in HCC cells. In addition, resistance to sorafenib-induced downregulation of AIB1 protein contributes to the acquired resistance of HCC cells to sorafenib-induced cell death. Collectively, our study implicates that AIB1 is a molecular target of sorafenib and downregulation of AIB1 contributes to the anti-tumor effects of sorafenib.
登录
查看更多内容
影响因子:
158.5
作者:
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者:
Bruix, Jordi
DOI:
10.1016/j.bbrc.2012.01.060
发表时间:
2012-02-17
影响因子:
3.1
作者:
Li, Xi-feng;Gong, Ren-yan;Shi, Le-hua
通讯作者:
Shi, Le-hua
影响因子:
11.2
作者:
Wilhelm, SM;Carter, C;Trail, PA
通讯作者:
Trail, PA
影响因子:
7
作者:
Davuluri, RV;Suzuki, Y;Zhang, MQ
通讯作者:
Zhang, MQ
影响因子:
11.2
作者:
Panka, DJ;Wang, W;Mier, JW
通讯作者:
Mier, JW